Frontier Biotechnologies(SH:688221) Zhong Guo Jing Ji Wang·2025-11-11 02:25Core Insights - Frontline Bio (688221.SH) reported a revenue of 103 million yuan for the year-to-date period ending Q3 2025, reflecting a year-on-year growth of 12.80% [1] - The company recorded a net loss attributable to shareholders of 160 million yuan and a net loss of 185 million yuan after excluding non-recurring items [1] - The net cash flow from operating activities was negative at 152 million yuan [1] Financial Performance - From 2018 to 2024, the net profit attributable to shareholders was as follows: -247 million yuan, -192 million yuan, -231 million yuan, -260 million yuan, -357 million yuan, -329 million yuan, and -201 million yuan [1] - The net profit after excluding non-recurring items during the same period was: -167 million yuan, -202 million yuan, -240 million yuan, -311 million yuan, -399 million yuan, -355 million yuan, and -327 million yuan [1] IPO and Fundraising - Frontline Bio went public on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2020, issuing 89.96 million shares at a price of 20.50 yuan per share [1] - The total amount raised from the initial public offering was 1.844 billion yuan, with a net amount of 1.717 billion yuan after expenses [2] - The company planned to use the raised funds for various projects, including clinical research for HIV inhibitors and pain relief patches, as well as for marketing network construction and working capital [2] Stock Performance - The highest stock price recorded on the first day of trading was 35.53 yuan, but the stock is currently in a state of decline [1] Control and Ownership - The actual controller of Frontline Bio is Dong Xie, a U.S. national with permanent residency in China [4]